Astrid van der Veldt

28PUBLICATIONS
108CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseasesEpidemiological modellingPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Aug 31, 2026
Neutralizing the IL-12/IL-23 p40 subunit prevents immune checkpoint blockade toxicity without compromising antitumor efficacy.

|Dec 26, 2025
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma.

Ruben Malmberg, Maaike M Hofman, Fatima Ashad

|Oct 15, 2025
COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study.

Quincy Hofsink, Birgit I Lissenberg-Witte, Sabine Haggenburg

|Apr 28, 2025
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

E J van Dijk, H H Nienhuis, A J M van den Eertwegh

|Apr 15, 2025
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

M Bloem, M M de Meza, A J M van den Eertwegh

|Mar 07, 2025
Size matters: Early progression of melanoma brain metastases after treatment with immune checkpoint inhibitors.

Sophie H A E Derks, Li Shen Ho, Stephan R Koene

Pageof 5

Frequent Collaborators

9 joint publications

Ellen W Kapiteijn

9 joint publications

Karijn Suijkerbuijk

7 joint publications

Michel W J M Wouters

4 joint publications

Willeke A M Blokx